Drugs in R & D

, Volume 9, Issue 2, pp 125–130 | Cite as

Mepolizumab

240563, Anti-IL-5 Monoclonal Antibody — GlaxoSmithKline, Anti-Interleukin-5 Monoclonal Antibody — GlaxoSmithKline, SB 240563
Adis R&D Profile

Keywords

Eosinophil Count Nasal Polyposis Eosinophilic Oesophagitis Hypereosinophilic Syndrome Sputum Eosinophil 

References

  1. 1.
    Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 176: 1062–1071, No. 11, 1 Dec 2007PubMedCrossRefGoogle Scholar
  2. 2.
    Cincinnati Childrens Hospital Medical Center. Cincinnati Children’ss Researchers Publish Positive Findings from Clinical Study of Investigational Treatment for Debilitating Allergic Disorder. Media Release: 20 Dec 2006. Available from URL: http://www.prnewswire.com Google Scholar
  3. 3.
    Zia-Amirhosseini P, Walls C, Patel B. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in mild asthmatics. Clinical Pharmacology and Therapeutics 65: 147, Feb 1999Google Scholar
  4. 4.
    Straumann A, Conus S, Kita H, et al. Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial. Gut 56 (Suppl. 3): 7, Oct 2007Google Scholar
  5. 5.
    Flood-Page P, Phipps S, Menzies-Gow A, et al. Effect of intravenous administration of an anti-IL-5 mAb (mepolizumab) on allergen-induced tissue eosinophilia, the late-phase allergic reaction and the expression of a marker of repair/remodeling in human atopic subjects. Journal of Allergy and Clinical Immunology 111 (Suppl.): 261 (plus poster), Feb 2003CrossRefGoogle Scholar
  6. 6.
    Menzies-Gow A, Flood-Page P, Compton C, et al. A double blind, placebo-controlled, parallel group study to assess the effect of mepolizumab (humanised monoclonal anti-IL-5 antibody) on bone marrow and peripheral blood eosinophils and eosinophil progenitors in atopic asthmatics. American Journal of Respiratory and Critical Care Medicine 165: B50, Part 2, Apr 2002Google Scholar
  7. 7.
    Phipps S, Flood-Page P, Menzies-Gow A, et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics. Journal of Allergy and Clinical Immunology 111 (Suppl.): 278 (plus oral presentation), Feb 2003CrossRefGoogle Scholar
  8. 8.
    Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’ss role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. American Journal of Respiratory and Critical Care Medicine 167: 199–204, 15 Jan 2003PubMedCrossRefGoogle Scholar
  9. 9.
    Weller PF, Gleich GJ, Busse WW, et al. Effects of mepolizumab, an anti-interleukin-5 monoclonal antibody, on blood eosinophil counts in patients with hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology 119 (Suppl.): 209, No. 1, Jan 2007CrossRefGoogle Scholar
  10. 10.
    Plötz S-G, Simon H-W, Darsow U, et al. Use of an antiinterleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. New England Journal of Medicine 349: 2334–2339, No. 24, 11 Dec 2003PubMedCrossRefGoogle Scholar
  11. 11.
    Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology 113: 115–119, No. 1, Jan 2004PubMedCrossRefGoogle Scholar
  12. 12.
    Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148, 23–30 Dec 2000PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations